Welcome to our dedicated page for Immucell news (Ticker: ICCC), a resource for investors and traders seeking the latest updates and insights on Immucell stock.
ImmuCell Corporation (ICCC) is a biotechnology leader focused on developing innovative health solutions for dairy and beef cattle. This page provides investors, industry professionals, and stakeholders with timely updates on the company’s scientific advancements, regulatory milestones, and market developments.
Access the latest press releases, earnings reports, and strategic announcements in one centralized location. Our curated collection includes updates on product innovations, FDA/USDA regulatory progress, financial performance, and partnerships that shape the animal health sector.
Key coverage areas include new product launches, financial results, manufacturing updates, and scientific research breakthroughs. Stay informed about developments in ImmuCell’s core segments: preventive care for newborn calves and mastitis treatment solutions for dairy cows.
Bookmark this page for direct access to verified information about ICCC’s contributions to livestock health and productivity. Check back regularly for objective updates on this pioneering animal health company.
ImmuCell (Nasdaq: ICCC) received an FDA Incomplete Letter for its Re-Tain NADA on December 23, 2025 after four of five technical sections were deemed complete and the contract manufacturer failed to satisfactorily address inspectional deficiencies. ImmuCell will pause further investment in Re-Tain, complete ongoing investigational studies, and pursue licensing or partnering options that avoid further capital or in-house manufacturing expenditure.
ImmuCell is simultaneously increasing First Defense field sales by 50%, expanding First Defense manufacturing, and expects a ~$2.3 million estimated non-cash impairment in Q4 2025 (Re-Tain net book value was $15.5M as of Sept 30, 2025). First Defense reported $27.8M TTM revenue and holds a 29% U.S. spend share in scour prevention; company estimates a $900M worldwide TAM for scours prevention.
ImmuCell (Nasdaq: ICCC) reported unaudited results for the quarter ended September 30, 2025. Q3 product sales fell 8% to $5.5M, while nine-month product sales rose 7% to $20.0M and twelve-month sales rose 16% to $27.8M. The company posted net income of $1.8M for the nine months versus a loss of $2.7M year-ago, driven by higher sales and margin recovery.
Gross margin improved to 42.6% for the nine months (vs. 27.3% prior year). Adjusted EBITDA was $751k for Q3 and $4.42M for nine months. Balance sheet highlights: cash $3.9M, net working capital $12.8M, stockholders' equity $29.8M. Re-Tain remains in investigational use with Michigan State University while management addresses prior backlog.
ImmuCell (Nasdaq: ICCC) will report unaudited financial results for the quarter ended September 30, 2025 after market close on Thursday, November 13, 2025. The company plans a conference call to review results on Friday, November 14, 2025 at 9:00 AM ET, accessible by dialing (844) 855-9502 (U.S.) or (412) 317-5499 (international). A teleconference replay will be available through November 21, 2025 using access code 7664668.
The company anticipates no change to preliminary third-quarter sales disclosed on October 7, 2025 and expects to file its Form 10-Q after market close on November 13, 2025. An updated corporate presentation will be posted under the Investors tab at www.immucell.com after the market close on November 13, 2025.
ImmuCell (Nasdaq: ICCC) announced leadership changes effective November 1, 2025: Olivier te Boekhorst began serving as President and CEO, succeeding Michael F. Brigham. At its October 29, 2025 meeting the board also appointed Timothy C. Fiori, who joined as CFO in April 2025, to the Board; Fiori will serve as CFO, Treasurer and Secretary.
Mr. Brigham will remain a board member and act as Special Advisor to the CEO through January 2026. The company plans a conference call on November 14, 2025 at 9:00 AM ET to discuss unaudited Q3 results and expects an updated corporate slide deck after market close on November 13, 2025.
ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited product sales for Q3 2025 and comparable periods. Q3 2025 sales were $5.5 million versus $6.0 million in Q3 2024. Year-to-date trends show $20.0 million for nine months and a trailing twelve-month total of $27.8 million, up from $23.8 million a year earlier.
Management attributes higher prior-period volume to distributor inventory rebuilds, warned of a second-half 2025 sales softening, noted a Non‑Administrative NADA submission in early January 2025, and began investigational use of Re‑Tain through year-end 2025 (not expected to generate revenue).
ImmuCell Corporation (Nasdaq: ICCC) has announced the appointment of Olivier te Boekhorst as its new President and CEO, effective November 1, 2025. Te Boekhorst, currently an Operating Partner at ARCHIMED and Chair of SeqCenter's Board, brings extensive industry experience from his 18-year tenure at IDEXX Laboratories, where he led significant growth initiatives in livestock diagnostics.
The transition includes current President and CEO Michael F. Brigham serving as Special Advisor for at least two months, while maintaining his Board position. Te Boekhorst's compensation package includes two stock option grants - an initial 76,673 shares at $5.90 per share and a subsequent grant of up to 85,000 shares, both vesting over three years.
ImmuCell Corporation (Nasdaq: ICCC) reported strong financial results for Q2 2025, with product sales increasing 18% to $6.4 million compared to Q2 2024. The company achieved significant improvements in profitability, posting net income of $502,000 ($0.06 per share) in Q2 2025, compared to a net loss of $1.5 million in Q2 2024.
Key financial metrics include gross margin improvement to 44% in Q2 2025 (up from 22% in Q2 2024), and cash position strengthening to $6.0 million as of June 30, 2025. The company has eliminated its order backlog and is building inventory for the peak selling season. Regarding Re-Tain®, ImmuCell has initiated Investigational Product use while reducing development expenses and exploring strategic options.
The company's stockholders' equity increased to $29.9 million, and Adjusted EBITDA improved to $1.4 million for the quarter.ImmuCell Corporation (Nasdaq: ICCC) has successfully refinanced its bank debt with Maine Community Bank (MCB). The company secured a new $2.33 million loan at 6.5% interest, which was used to pay off two existing loans: a $1.53 million MCB loan at 7% and a $768,209 FAME loan at 8%.
The refinancing eliminates approximately $1.95 million in balloon payments due in Q3 2026, extending the amortization schedule through Q3 2030. This move strengthens ImmuCell's financial position while maintaining its relationship with MCB. The company, which develops and manufactures health products for dairy and beef cattle, will discuss its Q2 2025 financial results in an upcoming conference call on August 15, 2025.
ImmuCell Corporation (Nasdaq: ICCC), an animal health company focused on dairy and beef cattle products, will announce its Q2 2025 financial results after market close on August 14, 2025. The company will host a conference call on August 15, 2025, at 9:00 AM ET to discuss the results.
ImmuCell manufactures First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal restrictions.
ImmuCell Corporation (Nasdaq: ICCC) reported strong preliminary Q2 2025 sales results, with total sales reaching $6.4 million, an 18% increase from Q2 2024. The company has successfully increased its production capacity to over $30 million per year and reduced its order backlog to under $100,000, down significantly from $3.4 million in May 2025.
The company is now evaluating additional investments to increase capacity by 33% to approximately $40 million to meet potential North American market demand. ImmuCell is also initiating Investigational Product use of Re-Tain® in H2 2025 to test market acceptance, following its Non-Administrative New Animal Drug Application submission in January 2025.
Twelve-month sales through June 2025 grew 22% to $28.3 million, demonstrating sustained growth across all reported periods. The company has transitioned from managing product allocations to pursuing new business opportunities now that distribution inventories have been rebuilt.
FAQ
What is the current stock price of Immucell (ICCC)?
What is the market cap of Immucell (ICCC)?
